One in three cancers diagnosed is a skin cancer, with 132,000 cases of melanoma occurring each year.1
Global incidence of melanoma continues to increase, and Caucasian populations are generally at much higher risk.
If caught early, melanoma is generally treatable. Testing for mutations in the BRAF oncogene has proven to be particularly effective in helping guide treatment options to medicines that “inhibit” cancer growth.
Roche Molecular enables oncology labs to test with confidence, offering both a sample preparation kit and the cobas® BRAF Mutation Test, which was used in pivotal clinical trials for vemurafenib to successfully select patients whose tumors harbor the V600E mutation in the BRAF gene.
- World Health Organization (WHO). Skin cancers. http://www.who.int/uv/faq/skincancer/en/. Accessed May 13, 2016.